Metoclopramida Kern Pharma (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone of the brain, decreasing the urge to vomit. At the same time it stimulates the release of acetylcholine in the gastrointestinal tract, enhancing smooth‑muscle contractions and promoting faster gastric emptying.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Dosing regimens may differ for acute nausea, chronic gastroparesis or migraine‑related nausea, and should follow local prescribing guidelines.

Safety data in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative is domperidone, another dopamine antagonist that does not cross the blood‑brain barrier as readily, resulting in fewer central nervous system side effects. However, domperidone has limited availability in some regions and may have cardiac QT‑prolongation concerns, whereas metoclopramide offers both anti‑emetic and pro‑kinetic actions but carries a higher risk of extrapyramidal reactions.

The injectable solution should be stored below 25 °C, in its original packaging, protected from light and moisture. Do not freeze the product. Before administration, inspect the vial for particulate matter or discoloration and use aseptic technique as per standard injection protocols.

Metoclopramida Kern Pharma is supplied for intramuscular or intravenous injection. The route, rate of infusion and duration are determined by the prescriber, taking into account the clinical indication and patient-specific factors. Intravenous administration should be performed slowly to reduce the risk of cardiovascular side effects.

Serious adverse events include extrapyramidal symptoms such as dystonia, tardive dyskinesia with prolonged use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, anaphylactic reactions, and rare cardiac arrhythmias. Patients should be instructed to seek immediate medical attention if they experience uncontrolled muscle movements, severe mood changes or signs of an allergic reaction.

Metoclopramida Kern Pharma is contraindicated in patients with known hypersensitivity to metoclopramide or any component of the formulation, in individuals with pheochromocytoma, and in those with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation, or hemorrhage.